CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Completes Initial R&D Program with the National Research Council of Canada
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced successful completion of its Master Collaborative Research Agreement (“the R&D Program”) with the National Research Council of Canada (“NRC”). The R&D program sought to investigate technical aspects and new opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions using Lexaria’s patented DehydraTECH(TM) technology with a primary goal to determine whether, through its processing, DehydraTECH causes the formation of a new molecular entity (“NME”). According to the update, all evidence aligns to confirm that no covalent-bonded NME is created with Lexaria’s technology. Processes or technologies…
